Journal of Oral Science Research ›› 2017, Vol. 33 ›› Issue (12): 1298-1301.DOI: 10.13701/j.cnki.kqyxyj.2017.12.015

• CONTENTSINBRIEF • Previous Articles     Next Articles

Expression Level and Clinical Efficacy of Multidrug Resistant Proteins before and after Neoadjuvant Chemotherapy in OSCC.

WU Li-bo, PAN Shu-ting, QIU Jia-xuan*.   

  1. Department of Oral&Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Received:2017-01-15 Online:2017-12-20 Published:2018-01-03

Abstract: Objective: To observe the relationship between therapeutic efficacy and 5-year survival rate of OSCC patients after neoadjuvant chemotherapy, and to explore the relationship between P-gp, MRP1, or GST-π and therapeutic efficacy after neoadjuvant chemotherapy. Methods: Seventy-seven OSCC paraffin specimens (50 valids and 27 invalids) were collected from the First Affiliated Hospital of Nanchang University. The 5-year survival time was followed up. Envision assay was used to determine the expression level of P-gp, MRP1, and GST-π. Thirty-three OSCC fresh specimens (18 valids and 15 invalids) were collected. qPCR and Western Blot assay were used to detect the expression level of P-gp, MRP1, and GST-π. Results: The Kaplan-Meier assay showed that 5-year survival rate of valid group was better than that of invalid group (P<0.05). The results of Envision, qPCR, and Western Blot showed that the increased expression levels of P-gp and MRP1 in valid group were significantly higher than those in invalid group (P<0.05). Conclusion: The 5-year survival rate of valid group was obviously higher than that of invalid group after the neoadjuvant chemotherapy. The expression levels of P-gp and MRP1 were related to therapeutic efficacy. The higher expression levels of P-gp and MRP1 were followed by the inferior therapeutic efficacy.

Key words: OSCC Neoadjuvant chemotherapy , Multidrug Resistant related proteins , 5-year survival rate

CLC Number: